HeartSciences reports FY2023 progress; MyoVista pivotal study enrollment complete

HeartSciences Inc.

Completed patient enrollment for MyoVista wavECG pivotal study; FDA submission on track for later 2023.
Expanded IP portfolio to 40 granted patents, including US, Korean, and Israeli patents for AI ECG.
Entered multi-year AI ECG algorithm development collaboration with Rutgers University health system.
Cash and cash equivalents $1.7M as of April 30, 2023; no revenue (development-stage company).
AMA issued new Category III reimbursement codes for AI ECG risk assessment, validating market.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HeartSciences Inc. reported financial results for fiscal year ended April 30, 2023.

Period: fiscal year ended April 30, 2023
Result: reported results

Exact text from the filing

Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today provided a business update and reported financial results for the fiscal year ended April 30, 2023.

View on SEC.gov

Browse all earnings releases →

HeartSciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-033460

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.